You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 124 No. 2, February 2006 TABLE OF CONTENTS
  Archives
  •  Online Features
  Laboratory Sciences
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (10)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Glaucoma
 •Alert me on articles by topic

Memantine Protects Neurons From Shrinkage in the Lateral Geniculate Nucleus in Experimental Glaucoma

Yeni H. Yücel, MD, PhD, FRCPC; Neeru Gupta, MD, PhD, FRCSC; Qiang Zhang, PhD; Andrew P. Mizisin, PhD; Michael W. Kalichman, PhD; Robert N. Weinreb, MD

Arch Ophthalmol. 2006;124:217-225.

Objective  To determine whether memantine as a treatment for glaucoma prevents neuron shrinkage in the lateral geniculate nucleus, the major target for retinal ganglion cells.

Methods  Sixteen monkeys with right-eye unilateral experimental glaucoma for 14 months were studied and treated with memantine (n = 9) or vehicle only (n = 7). Left lateral geniculate nucleus relay neurons (layers 1, 4, and 6) were examined following parvalbumin immunolabeling. Cell body cross-sectional areas and neuron numbers were assessed using unbiased methods. Memantine- and vehicle-treated glaucoma groups were compared using t tests and analysis of covariance.

Results  Compared with vehicle-treated animals, memantine-treated animals showed significantly less mean ± SD neuron shrinkage in layers 1 (–4.0% ± 13.9% vs 28.2% ± 17.4%; P = .001) and 4 (24.9% ± 10.0% vs 37.2% ± 12.3%; P = .04). For layer 6, the difference was not statistically significant (34.2% ± 10.1% vs 45.3% ± 14.5%; P = .10). Analysis of covariance results showed significantly less neuron shrinkage in the memantine-treated group for layers 1, 4, and 6 (P < .001; P < .02; and P < .04, respectively). This difference was greatest in layer 1. In each of these layers, neuron numbers did not differ significantly between groups.

Conclusion  Monkeys with glaucoma that were treated with memantine showed significantly less neuron shrinkage in the lateral geniculate nucleus than the vehicle-treated glaucoma group.

Clinical Relevance  The finding that memantine protects adult visual neurons from transsynaptic atrophy in experimental glaucoma could have therapeutic value. Currently, memantine is being tested in an ongoing clinical trial as a treatment for glaucoma.


Author Affiliations: Departments of Ophthalmology and Vision Sciences (Drs Yücel and Gupta) and Laboratory Medicine and Pathobiology (Drs Yücel and Gupta), the Health Sciences Research Center (Drs Yücel, Gupta, and Zhang), and Glaucoma and Nerve Protection Unit (Dr Gupta), St Michael's Hospital, University of Toronto, Toronto, Ontario; Departments of Pathology (Drs Mizisin and Kalichman) and Ophthalmology (Dr Weinreb) and the Hamilton Glaucoma Center (Dr Weinreb), University of California, San Diego.



THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

How much is the brain involved in glaucoma?
Alm
Br. J. Ophthalmol. 2006;90:663-664.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2006 American Medical Association. All Rights Reserved.